Table 1.
Baseline Patient Characteristics at Initiation of TNF-α Inhibitor Therapy
| Characteristics | Total (n=113) | Infliximab (n=83) | Adalimumab (n=30) | p-value |
|---|---|---|---|---|
| Demographic features | ||||
| Age, yr | 38.4±17.2 | 38.2±18.2 | 39.0±14.1 | 0.819 |
| Sex | 0.165 | |||
| Male | 71 (62.8) | 49 (59.0) | 22 (73.3) | |
| Female | 42 (37.2) | 34 (41.0) | 8 (26.7) | |
| Smoking | 0.287 | |||
| Non-smoker | 85 (75.2) | 62 (74.7) | 23 (76.7) | |
| Ex-smoker | 22 (19.5) | 15 (18.1) | 7 (23.3) | |
| Current smoker | 6 (5.3) | 6 (7.2) | 0 | |
| BMI, kg/cm2 | 21.2±3.2 | 21.1±2.7 | 21.5±4.3 | 0.684 |
| Disease extent | 0.820 | |||
| Extensive | 53 (46.9) | 37 (44.6) | 16 (53.3) | |
| Left-side | 56 (49.6) | 43 (51.8) | 13 (43.3) | |
| Proctitis | 4 (3.5) | 3 (3.6) | 1 (3.3) | |
| Concomitant medications | ||||
| Aminosalicylates* | 102 (90.3) | 73 (88.0) | 29 (96.7) | 0.283 |
| Corticosteroids | 41 (36.3) | 27 (32.5) | 14 (46.7) | 0.168 |
| Immunomodulators† | 59 (52.2) | 41 (49.4) | 18 (60.0) | 0.319 |
| Disease duration, mo‡ | 66.1±62.7 | 66.1±61.4 | 66.0±67.1 | 0.992 |
| Extraintestinal manifestations | ||||
| Joint | 14 (12.4) | 11 (13.3) | 3 (10.0) | 0.757 |
| Skin | 6 (5.3) | 4 (4.8) | 2 (6.7) | 0.655 |
| Oral | 3 (2.7) | 1 (1.2) | 2 (6.7) | 0.172 |
| Partial Mayo score | 6.4±1.6 | 6.6±1.5 | 6.0±1.8 | 0.095 |
| Stool frequency subscore | 2.5±0.7 | 2.5±0.7 | 2.3±0.8 | 0.250 |
| Rectal bleeding subscore | 1.9±0.8 | 1.9±0.8 | 1.9±0.7 | 0.838 |
| PGA subscore | 2.1±0.9 | 2.2±0.9 | 1.8±1.0 | 0.028 |
| Biochemical parameters at initiation | ||||
| CRP, mg/L | 23.4±38.6 | 25.4±41.3 | 17.9±29.6 | 0.403 |
| Hemoglobin, g/dL | 12.1±2.3 | 11.9±2.3 | 12.7±2.2 | 0.121 |
| Albumin, g/dL | 3.7±0.6 | 3.7±0.6 | 3.8±0.6 | 0.201 |
| ESR, mm/hr | 44.6±32.6 | 45.2±33.0 | 43.1±32.0 | 0.696 |
| Follow-up length, mo | 25.8±18.4 | 26.3±19.6 | 24.5±14.5 | 0.964 |
Data are presented as mean±SD or number (%).
TNF, tumor necrosis factor; BMI, body mass index; PGA, Physician’s Global Assessment; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.
*Includes mesalazine, sulfasalazine, aminosalicylic acid, and balsalazide; †Includes azathioprine, 6-mercaptopurine, and methotrexate; ‡Duration from the first diagnosis of ulcerative colitis to TNF-α inhibitor administration.